Alpha Cognition Inc. Common Stock (ACOG) は上場企業です 金融 セクターの Financial - Conglomerates 業界で事業展開. 本社所在地は Vancouver, BC, カナダ. 現CEOは Michael E. McFadden.
ACOG を有する IPO日 2024-11-12, 5 名の正社員, に上場 NASDAQ Global Market, 時価総額 $102.82M.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
